Markus Rihl
Rheumatologische Schwerpunktpraxis,
Jahnstr. 36, 83278 Traunstein
Germany
Research Article
Intravenous Glucocorticoid Pulse Therapy in Active, NSAID Refractory Axial An
Author(s): Markus Rihl, Niklas Baerlecken, Birgitt Wiese, Reinhold E. Schmidt and Henning ZeidlerMarkus Rihl, Niklas Baerlecken, Birgitt Wiese, Reinhold E. Schmidt and Henning Zeidler
Objective: High dose intravenous glucocorticoid (IVGC) pulse therapy is known to effectively reduce inflammatory signs and symptoms in patients with active inflammatory conditions. However, the efficacy of IVGC in ankylosing spondylitis (AS) is not clearly established.
Methods: We performed a retrospective analysis with repeated measurements including patients with active, NSAID refractory axial AS (n=15) who underwent high dose IVGC pulse therapy. Parameters of clinical and humoral disease activity were compared to active AS patients (n=14) under continuous anti-TNF treatment. Patients were seen every 3 months and followed up for a total period of 12 months.
Results: Both IVGC pulse and anti-TNF therapy lead to a significant and sustained reduction of the mean bath ankylosing spondylitis disease activity index (BASDAI 7.. View More»
